Health
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved a once-daily oral GLP‑1 medicine to help people reduce excess body weight and maintain weight loss over the long term. The Novo Nordisk treatment marks a milestone in medical obesity care by offering the convenience of a pill with weight-loss results comparable to therapies that have typically required injections. The approval provides a new option for patients who need medical support for obesity but have been reluctant to use needles.
About this update from Novo Nordisk A/s Class B
[{"type":"text","content":"The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from baseline. The therapy is also indicated to lower the risk of major cardiovascular events* such as heart attack and stroke in certain patients. Novo Nordisk expects to launch the pill in the United States in early January 2026.","length":523,"tagName":"p","attribs":{}},{"type":"text","content":"JAKARTA, Indonesia, Jan. 28, 2026 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved a once-daily oral GLP‑1 medicine to help people reduce excess body weight and maintain weight loss over the long term. The Novo Nordisk treatment marks a milestone in medical obesity care by offering the convenience of a pill with weight-loss results comparable to therapies that have typically required injections. The approval provides a new option for patients who need medical support for obesity but have been reluctant to use needles.","length":545,"tagName":"p"},{"type":"text","content":"Data from the global OASIS 4 clinical trial showed the once-daily pill delivered significant weight-loss results. Participants lost an average of 16.6% of their starting body weight after about a year of consistent treatment.[1] One in three patients achieved weight loss of more than 20%—a level that can translate into meaningful improvements in daily functioning and quality of life for people living with obesity. The findings suggest the oral option can deliver weight loss comparable to the once-weekly injectable version already available.","length":551,"tagName":"p"},{"type":"text","content":"Beyond weight loss, the therapy is also approved to reduce the risk of serious heart and cardiovascular problems, including heart attack and stroke, in certain patient groups. Clinical data showed approximately a 20% reduction in cardiovascular risk among patients with heart disease who also have obesity or overweight. This means obesity management with this therapy addresses more than appearance—it offers meaningful protection for heart health and the potential to extend lifespan.","length":486,"tagName":"p"},{"type":"text","content":""The pill is here. With...